HK Stock Market Move | SUNSHINE PHARMA (06887) rose more than 4% in the morning session. The company announced a major strategic cooperation agreement with XTALPI.

SUNSHINE PHARMA (06887) rose by over 4% in the morning session, reaching 4.06% by press time, standing at HK$46.68, with a trading volume of HK$13.8169 million. On the news front, on January 26, SUNSHINE PHARMA and XTALPI announced the signing of a major strategic cooperation agreement. This cooperation is not only a strategic leap for SUNSHINE PHARMA to fully embrace the "AI+Siasun Robot & Automation" research and development paradigm and achieve R&D upgrade, but also a strong validation of the commercial value of XTALPI's general AI platform in the scenario of large pharmaceutical companies. It was revealed that the two parties plan to establish a joint venture company, deeply integrating the technological advantages of the XTALPI AI+Siasun Robot & Automation drug development platform, as well as SUNSHINE PHARMA's deep accumulation in multi-target development data, biological insights, and pipeline development experience. Through the joint establishment of AI+Siasun Robot & Automation laboratories, the development of non-clinical drug large models, and solving many long-standing challenges in drug development, the two companies aim to achieve comprehensive cooperation in underlying technology and new drug pipeline development and commercialization. In this cooperation, SUNSHINE PHARMA is expected to invest billions of RMB, with the goal of creating an industry-leading AI drug development engine and achieving technology going global, building a diversified profit model of "pipeline co-creation + technology win-win".